Exact Sciences Corp. of Madison raised $73.4 million in a secondary stock offering after selling 6.3 million shares of common stock at $12.35 per share. That includes an option for the underwriters to purchase an additional 5.5 million shares beyond the initial offering.
The company will use the funds for general corporate purposes, including efforts to gain FDA approval of its stool-based screening test for colorectal cancer.
